FDA Rejects Merck's Proposed Successor to Vioxx
Friday, April 27, 2007 NEW YORK — Merck & Co. (MRK) said Friday that U.S. regulators have rejected its experimental arthritis drug Arcoxia, the drugmaker's follow-up to Vioxx, saying it could not be approved without new supportive data. Wall Street had expected the negative decision by the U.S. Food... Sign in to see full entry.
![Associated Content](http://www.associatedcontent.com/user/8835/mandaleesrc="http://www.associatedcontent.com/images/house_ads/cp-sp6.gif" border="0"></a>){kind=link}